NCT03720717 is a Phase 4 clinical trial of Baclofen 10mg in Pain, sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT03720717?

NCT03720717 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT03720717?

Interventions in NCT03720717: Baclofen 10mg, Placebo.

Is NCT03720717 still recruiting?

NCT03720717 is currently terminated. Last updated 5 September 2024.

Are results published for NCT03720717?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-09-05 · How we verify

NCT03720717

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baclofen as a Perioperative Analgesic Adjuvant

Terminated Phase 4 Results posted Last updated 5 September 2024

What this trial tests

Phase 4 trial testing Baclofen 10mg in Pain in 34 participants. Terminated before completion.

Timeline

27 October 2020

Primary endpoint
28 October 2022

28 October 2022

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	34
Start date	27 October 2020
Primary completion	28 October 2022
Estimated completion	28 October 2022
Sites	1 location across United States

Drugs / interventions tested

Baclofen 10mg — full drug profile →
Placebo

Conditions studied

Pain — all drugs for Pain →

Sponsor

University of Alabama at Birmingham

Who can join

19 and older, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Postoperative Opioid Requirements Primary · From 0 hours post-operatively to 24 hours post-operatively

Patients Patients' opioid requirements for acceptable pain control will be assessed based on the total oral morphine equivalent needed for post operative pain control.

Group	Value	95% CI
Opioid Tolerant - Baclofen	85.5	± 33.6
Opioid Tolerant - Placebo	96.8	± 17.1
Opioid Naive - Baclofen	69.9	± 10.0
Opioid Naive - Placebo	40.4	± 11.7

Sponsor's own description

The purpose of this study is to determine whether a single, oral dose of baclofen alters postoperative opioid requirements.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Use of Baclofen Premedication as an Analgesic Adjuvant in Patients Undergoing Percutaneous Nephrolithotripsy: A Placebo-Controlled, Double-Blind Randomized Trial.
Mandabach M, Deichmann P, Massoll A, Graves S, et al · · 2024 · PMID 39130904 · DOI 10.7759/cureus.64235

Verify or expand the search:

Other trials of Baclofen 10mg

Trials testing the same drug.

NCT05617118 — BTA vs Baclofen for Pelvic Myofascial Pain Syndrome · unknown
NCT04251819 — Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers · Phase 2, PHASE3 · terminated

Other recruiting trials for Pain

Currently open trials in the same condition.

NCT07533409 — Tactile and Pain Sensory Thresholds and Hand Grip Strength · recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03720717 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 5 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03720717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing